|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Pfizer, Inc. (PFE), a global drug developer and manufacturer. |
|---|---|
| Transferring Party | Vicuron Pharmceuticals, Inc. (MICU), a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. |
| Sector | Biopharmaceuticals |
| Date | September 14, 2005 |
| Analysis Gives Pfizer two new product candidates currently under review at the FDA: anidulafungin for fungal infections and dalbavancin for Gram-positive infections, bolstering its portfolio of anti-infective drugs. Deal value: $1.9 billion | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |